Merck 1Q Revenues: $5.8 billion (+1%) 1Q Earnings: $3.3 billion (+94%) Comments: Worldwide sales of Singulair were $1.1 billion (+10%); Cozaar and Hyzaar sales were $847 million (+6%); Fosamax and Fosamax Plus D sales were $470 million (-37%); Januvia, Janumet and Isentress sales were $1.8 billion (+14%). Worldwide sales of vaccines were $986 million in the quarter (+9%). Combined worldwide sales of Zetia and Vytorin, as reported by the Merck/Schering-Plough joint venture, were $1.2 bi...